Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 14%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health has demonstrated strong growth potential, notably with a reported 70% year-over-year subscriber growth in the fourth quarter, which bodes well for continued revenue growth as the company adjusts for shipping headwinds. The company's international expansion, now including the UK market and integration of Zava, is contributing incremental growth while diversifying revenue streams beyond their core specialties. Furthermore, Hims' strategic positioning to capitalize on weight-loss drug developments and the expansion of its service offerings mitigates concentration risk, ensuring a more stable financial outlook as they navigate through their business transition.

Bears say

Hims & Hers Health's outlook has been downgraded due to a significant slowdown in revenue growth, highlighted by disappointing fourth-quarter 2025 earnings and weak first-quarter 2026 guidance. Revenue estimates for 2027 have been revised down from $3.7 billion and $535 million in EBITDA to $3.1 billion and $404 million, respectively, reflecting a considerable decline in expected performance. Additionally, the company faces increased legal and regulatory risks, compounding the challenges posed by its anticipated lower-than-expected performance for the upcoming fiscal year.

HIMS has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 14 analysts, HIMS has a Buy consensus rating as of Apr 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.